ArticleDrug and alcohol dependence2025
Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study.
Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone.Drug and alcohol dependence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOpioid overdose survivors are at high risk for subsequent overdose. There are few evaluations using real-world data to compare overdose risk after receipt of different addiction treatment modalities.
objectiveTo assess the association between receipt of different addiction treatment modalities and risk of subsequent opioid overdose among opioid overdose survivors.
designSurvival analysis comparing time-to-subsequent overdose within a cohort of opioid overdose survivors using a linked state-wide individual level data of different addiction treatment modalities: opioid agonists treatments (OAT, i.e., methadone or buprenorphine) and non-medication based inpatient addiction treatments (medically supervised opioid withdrawal and extended inpatient treatment). SUBJECTS: Opioid-involved overdose survivors (N = 4089) admitted to a hospital or emergency department in Connecticut between May 2016 and December 2017 MAIN MEASURES: Time-to-subsequent overdose (fatal or non-fatal) and time-to-subsequent fatal overdose KEY
resultsFollowing the index overdose, 467 (11.4 %) experienced another overdose event within 12 months (87 fatal and 380 non-fatal), 35 % received OAT (25 % buprenorphine and 13 % methadone), and 21 % received inpatient addiction treatment (19 % medically supervised opioid withdrawal and 8 % extended inpatient treatment). In survival analyses adjusted for demographics, incarceration, and receipt of non-OAT opioids or benzodiazepines, receipt of methadone (aHR 0.41, 95 % CI: 0.26-0.66) or buprenorphine (aHR 0.72, 95 % CI: 0.53-0.98) was associated with a decreased risk of subsequent overdose compared to no receipt of methadone or buprenorphine, respectively. Neither medically supervised opioid withdrawal (aHR 1.08, 95 % CI: 0.77-1.50) nor extended inpatient treatment (aHR 0.90, 95 % CI: 0.53-1.54) was associated with reduced risk of subsequent overdose. Neither OAT nor non-medication based inpatient treatment modalities were associated with a change in risk of subsequent fatal overdose; benzodiazepine exposure was associated with increased risk (aHR 2.65, 95 % CI: 1.66-4.23).
conclusionUsing statewide data, our findings underscore the importance of OAT to reduce risk of subsequent overdose following a non-fatal opioid overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.